Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma Holdings announces the appointment of Eric J. Ende as Chairman of the Board, effective October 1, 2022. Ende succeeds Herbert J. Conrad, who will remain on the board as an independent director. The leadership change reflects the company's progress and aims to enhance its strategic direction. Ende, who joined the board in 2017, brings extensive experience from previous roles, including at Genzyme and Merrill Lynch. Matinas BioPharma focuses on its lipid nanocrystal technology for drug delivery, with ongoing clinical trials for products like MAT2203 and MAT2501.
Matinas BioPharma (MTNB) announced that its CEO, Jerome D. Jabbour, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 p.m. ET in New York City. The company is focused on enhancing intracellular delivery using its lipid nanocrystal platform technology. They have two clinical-stage assets: MAT2203, an oral antifungal, and MAT2501, an oral treatment for bacterial infections. Investors can access a webcast of the presentation on their website following the event.
Matinas BioPharma Holdings (MTNB) reported significant progress with MAT2203, its lead candidate for cryptococcal meningitis, enrolling 75% of patients in Cohort 4 of the EnACT study. Topline data is expected by early Q4 2022. The FDA has clarified a streamlined Phase 3 trial design, with an anticipated start in Q1 2023. The company has $38.5 million in cash, adequate to support operations through 2023. Management expects ongoing collaboration with BioNTech on mRNA applications. However, a potential partnership for LYPDISO is halted. The net loss for Q2 2022 was $5.9 million.
Matinas BioPharma (NYSE: MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the BTIG Biotechnology Conference on August 8, 2022, at 2:00 p.m. ET, alongside investor meetings. This hybrid conference will take place at The St. Regis New York. The company aims to enhance intracellular delivery through its lipid nanocrystal (LNC) platform, developing drug candidates like MAT2203 for antifungal treatments and MAT2501 for bacterial infections. Collaborative efforts include partnerships with BioNTech and Gilead Sciences.
Matinas BioPharma (NYSE: MTNB) announced a conference call on August 11, 2022, at 8:30 a.m. ET to discuss their second-quarter operational and financial results. Interested participants can join by calling (877) 407-5976 or (412) 902-0031 and use conference ID 13730276. The live webcast will be available on the company's website, where it will also be archived for 90 days. Matinas focuses on enhancing the intracellular delivery of nucleic acids and small molecules using its lipid nanocrystal (LNC) platform.
Matinas BioPharma (MTNB) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has recommended MAT2203 for orphan medicinal product designation for treating cryptococcosis. Previously, the FDA granted MAT2203 Orphan Drug, QIDP, and Fast Track designations. This designation provides potential market exclusivity and reduction in application fees. MAT2203 is an oral formulation of amphotericin B, currently completing Phase 2 trials, targeting invasive fungal infections like cryptococcal meningitis.
Matinas BioPharma (NYSE AMER: MTNB) will be represented by CEO Jerry Jabbour at the LD Micro Invitational XII Conference on June 7, 2022, at 3:30 p.m. ET in Westlake Village, California. Investors interested in meeting management can coordinate through the conference. A live webcast of the presentation will be accessible via the Company’s website, with a replay available for 90 days post-event. Matinas focuses on advancing its lipid nanocrystal (LNC) technology for drug delivery, currently developing two clinical assets: MAT2203 and MAT2501.
Matinas BioPharma announced a collaboration with BioNTech to combine mRNA with its lipid nanocrystal (LNC) technology. Enrollment for Cohort 4 of the EnACT study for MAT2203 is ongoing, with topline data expected in Q3 2022. Feedback from a recent FDA meeting suggests a streamlined pathway for a New Drug Application with just one confirmatory trial for MAT2203. The company reported $43.9 million in cash, sufficient to fund operations through 2023, despite a net loss of $6.0 million in Q1 2022.
Matinas BioPharma Holdings (MTNB) announced a conference call on May 12, 2022, at 8:30 AM ET to discuss Q1 2022 operational and financial results. The company focuses on innovative intracellular delivery technologies using its lipid nanocrystal platform. Key assets include MAT2203, an oral antifungal in Phase 2 trials, and MAT2501, an oral formulation for bacterial infections currently in Phase 1. Collaborations with leading firms like BioNTech and Gilead strengthen its pipeline. The webcast will be available on Matinas' website and archived for 90 days.
Matinas BioPharma (MTNB) announced that CEO Jerry Jabbour is set to present at the 12th Annual BioNJ BioPartnering Conference, occurring virtually from May 9-13, 2022. His presentation is scheduled for May 10, from 11:00 a.m. to 12:30 p.m. ET. The conference aims to foster collaboration in the biopharmaceutical sector, and the company will leverage the BioPartnering 1:1 feature for one-on-one meetings. Matinas BioPharma focuses on innovative intracellular delivery solutions using its lipid nanocrystal platform and is currently advancing several product candidates, including MAT2203 and MAT2501.